ATE406881T1 - Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung - Google Patents
Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlungInfo
- Publication number
- ATE406881T1 ATE406881T1 AT02733811T AT02733811T ATE406881T1 AT E406881 T1 ATE406881 T1 AT E406881T1 AT 02733811 T AT02733811 T AT 02733811T AT 02733811 T AT02733811 T AT 02733811T AT E406881 T1 ATE406881 T1 AT E406881T1
- Authority
- AT
- Austria
- Prior art keywords
- alpha
- beta unsaturated
- radiation
- toxicity
- arylsulphones
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27199001P | 2001-02-28 | 2001-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE406881T1 true ATE406881T1 (de) | 2008-09-15 |
Family
ID=23037934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02733811T ATE406881T1 (de) | 2001-02-28 | 2002-02-28 | Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung |
Country Status (10)
Country | Link |
---|---|
US (1) | US6667346B2 (de) |
EP (1) | EP1370253B8 (de) |
JP (1) | JP4302986B2 (de) |
KR (1) | KR100850331B1 (de) |
AT (1) | ATE406881T1 (de) |
AU (1) | AU2002305942B2 (de) |
CA (1) | CA2439288C (de) |
DE (1) | DE60228692D1 (de) |
IL (2) | IL157541A0 (de) |
WO (1) | WO2002069892A2 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004510761A (ja) | 2000-10-05 | 2004-04-08 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 増殖性疾病を治療するための置換(e)−スチリルベンジルスルホン |
ES2373945T3 (es) * | 2002-02-28 | 2012-02-10 | Temple University - Of The Commonwealth System Of Higher Education | Bencilsulfonas de (e)-2,6-dialcoxiestirilo amino sustituido sustituidas en 4 para tratar trastornos proliferativos. |
IL163608A0 (en) * | 2002-02-28 | 2005-12-18 | Univ Temple | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders |
JP5196787B2 (ja) * | 2003-11-14 | 2013-05-15 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 増殖性疾患を治療するためのα,β−不飽和スルホキシド |
US7649013B2 (en) * | 2003-11-26 | 2010-01-19 | Arqule, Inc. | Methods of protecting against radiation injury |
EA012980B1 (ru) | 2004-03-16 | 2010-02-26 | Темпл Юниверсити Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн | Замещённые фенокси- и фенилтиопроизводные для лечения пролиферативных нарушений |
ATE529106T1 (de) | 2004-06-24 | 2011-11-15 | Univ Temple | Alpha-, beta-ungesättigte sulfone, sulfonoxide, sulfonimide, sulfinimide, acylsulfonamide und acylsulfinamide und therapeutische verwendungen damit |
EP1773353B1 (de) * | 2004-07-19 | 2011-02-09 | Onconova Therapeutics, Inc. | Formulierungen für die parenterale verabreichung von (e)-2,6-dialkoxystryryl 4-substituierten benzylsulfonen |
US7537572B2 (en) | 2004-10-22 | 2009-05-26 | General Patent, Llc | Treatment or pre-treatment for radiation/chemical exposure |
AU2006204103B2 (en) * | 2005-01-05 | 2011-11-24 | Temple University Of The Commonwealth System Of Higher Education | Treatment of drug-resistant proliferative disorders |
CA2599169C (en) * | 2005-02-25 | 2013-10-22 | Temple University - Of The Commonwealth System Of Higher Education | Synthesis of (e)-alpha, beta unsaturated sulfides, sulfones, sulfoxides and sulfonamides |
WO2006104668A2 (en) * | 2005-03-11 | 2006-10-05 | Temple University - Of The Commonwealth System Of Higher Education | Composition and methods for the treatment of proliferative diseases |
US20110028504A1 (en) * | 2005-07-29 | 2011-02-03 | Onconova Therapeutics, Inc. | Formulation of radioprotective alpha beta unsaturated aryl sulfones |
EP1864692A1 (de) * | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Verwendung von peptiden zum Schutz von Strahlenschäden |
JP2007302640A (ja) * | 2006-05-15 | 2007-11-22 | Natl Inst Of Radiological Sciences | 抗放射線被ばく障害剤 |
JP5275985B2 (ja) * | 2006-07-28 | 2013-08-28 | オンコノバ・セラピューティックス・インコーポレーテッド | 放射線保護α,β不飽和アリールスルホン類の処方 |
WO2008027049A1 (en) | 2006-08-30 | 2008-03-06 | Temple University - Of The Commonwealth System Of Higher Education | Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
US8273787B2 (en) * | 2006-09-15 | 2012-09-25 | Onconova Therapeutics, Inc | Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions |
WO2008076270A2 (en) * | 2006-12-13 | 2008-06-26 | Temple University-Of The Commonwealth System Of Higher Education | Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof |
US20100049284A1 (en) * | 2008-05-15 | 2010-02-25 | The Catholic University Of America | Use of heat to treat biological systems exposed to damaging radiation |
CN102231983A (zh) * | 2008-10-01 | 2011-11-02 | 北卡罗来纳大学查珀尔希尔分校 | 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护 |
WO2010039997A2 (en) * | 2008-10-01 | 2010-04-08 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
WO2010075026A2 (en) * | 2008-12-16 | 2010-07-01 | Onconova Therapeutics Inc | Methods for determining efficacy of a therapeutic regimen against deleterious effects of cytotoxic agents in human |
JP2012526850A (ja) | 2009-05-13 | 2012-11-01 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | サイクリン依存性キナーゼ阻害剤及びその用法 |
CN104320971A (zh) * | 2010-03-24 | 2015-01-28 | 安哥洛华治疗公司 | 用于预防和治疗创伤的组合物和方法 |
CA2792913C (en) | 2010-03-26 | 2020-01-21 | Onconova Therapeutics, Inc. | Improved stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone |
GB201010359D0 (en) | 2010-06-21 | 2010-08-04 | Univ Nottingham | Compounds for treating proliferative disorders |
AU2011329763A1 (en) | 2010-11-17 | 2013-05-09 | Brigham And Women's Hospital | Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6 |
US10207989B2 (en) | 2012-09-20 | 2019-02-19 | Temple University—Of the Commonwealth System of Higher Education | Substituted alkyl diaryl derivatives, methods of preparation and uses |
ME03557B (de) | 2013-03-15 | 2020-07-20 | G1 Therapeutics Inc | Vorübergehender schutz von normalen zellen während einer chemotherapie |
JP6435315B2 (ja) | 2013-03-15 | 2018-12-05 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 高活性抗新生物薬及び抗増殖剤 |
CN104230770B (zh) * | 2013-06-17 | 2017-11-21 | 华夏生生药业(北京)有限公司 | 苯乙烯基砜类化合物、其制备方法以及其作为神经保护剂的应用 |
AU2015204239B2 (en) * | 2014-01-06 | 2018-04-19 | Hackensack University Medical Center | Method for treating skin cancer using radiation therapy |
US9717735B2 (en) | 2014-04-17 | 2017-08-01 | G1 Therapeutics, Inc. | Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
EP3191098A4 (de) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Kombinationen und dosierschemen zur behandlung von rb-positiven tumoren |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
US10383831B2 (en) | 2015-08-03 | 2019-08-20 | Temple University—Of the Commonwealth System of Higher Education | 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use |
CN106432011B (zh) * | 2016-09-18 | 2018-11-02 | 中国医学科学院放射医学研究所 | 一类具有辐射防护作用的新化合物、其制备方法及其药物应用 |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
PT3691620T (pt) | 2017-10-05 | 2022-10-06 | Fulcrum Therapeutics Inc | Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd |
EP4001263B1 (de) * | 2019-07-18 | 2024-03-27 | Huaxiashengsheng Pharmaceutical Beijing Co., Ltd. | Carbamatsubstituierte styrylsulfonverbindung, verfahren zu ihrer herstellung und ihre verwendung |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU741042B2 (en) * | 1997-10-03 | 2001-11-22 | Temple University - Of The Commonwealth System Of Higher Education | Styryl sulfone anticancer agents |
US6201154B1 (en) | 1999-03-31 | 2001-03-13 | Temple University-Of The Commonwealth Of Higher Education | Z-styryl sulfone anticancer agents |
WO2000059495A1 (en) | 1999-04-02 | 2000-10-12 | Temple University - Of The Commonwealth System Of Higher Education | (e)-styryl sulfone anticancer agents |
AU3381399A (en) * | 1999-04-02 | 2000-10-23 | Temple University - Of The Commonwealth System Of Higher Education | Styryl sulfone anticancer agents |
EP1223923B1 (de) * | 1999-10-12 | 2010-03-31 | Temple University of the Commonwealth System of Higher Education | Ungesättigte arylsulfone zum schutz von normalen zellen gegen die zytotoxische wirkung von chemotherapeutika |
US6664287B2 (en) * | 2000-03-15 | 2003-12-16 | Bethesda Pharmaceuticals, Inc. | Antioxidants |
WO2001076592A1 (en) * | 2000-04-06 | 2001-10-18 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neural regeneration |
US6486210B2 (en) | 2000-04-14 | 2002-11-26 | Temple University—Of the Commonwealth System of Higher Education | Substituted styryl benzylsulfones for treating proliferative disorders |
IL157540A0 (en) * | 2001-02-28 | 2004-03-28 | Univ Temple | N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof |
-
2002
- 2002-02-28 CA CA2439288A patent/CA2439288C/en not_active Expired - Lifetime
- 2002-02-28 AU AU2002305942A patent/AU2002305942B2/en not_active Expired
- 2002-02-28 US US10/085,745 patent/US6667346B2/en not_active Expired - Lifetime
- 2002-02-28 DE DE60228692T patent/DE60228692D1/de not_active Expired - Lifetime
- 2002-02-28 KR KR1020037011357A patent/KR100850331B1/ko active IP Right Grant
- 2002-02-28 IL IL15754102A patent/IL157541A0/xx unknown
- 2002-02-28 AT AT02733811T patent/ATE406881T1/de not_active IP Right Cessation
- 2002-02-28 JP JP2002569071A patent/JP4302986B2/ja not_active Expired - Lifetime
- 2002-02-28 WO PCT/US2002/006107 patent/WO2002069892A2/en not_active Application Discontinuation
- 2002-02-28 EP EP02733811A patent/EP1370253B8/de not_active Expired - Lifetime
-
2003
- 2003-08-21 IL IL157541A patent/IL157541A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
JP4302986B2 (ja) | 2009-07-29 |
CA2439288C (en) | 2011-08-09 |
IL157541A (en) | 2010-05-31 |
WO2002069892A3 (en) | 2002-11-07 |
KR20030086596A (ko) | 2003-11-10 |
DE60228692D1 (de) | 2008-10-16 |
AU2002305942B2 (en) | 2006-10-26 |
EP1370253B1 (de) | 2008-09-03 |
WO2002069892A2 (en) | 2002-09-12 |
CA2439288A1 (en) | 2002-09-12 |
IL157541A0 (en) | 2004-03-28 |
US20030060505A1 (en) | 2003-03-27 |
EP1370253B8 (de) | 2008-11-26 |
JP2004525908A (ja) | 2004-08-26 |
KR100850331B1 (ko) | 2008-08-04 |
EP1370253A2 (de) | 2003-12-17 |
US6667346B2 (en) | 2003-12-23 |
EP1370253A4 (de) | 2005-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE406881T1 (de) | Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung | |
WO2005044181A3 (en) | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors | |
EA200000087A1 (ru) | Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта | |
WO2005065074A3 (en) | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors | |
JP2008519047A5 (de) | ||
BRPI0409919A (pt) | combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese | |
MXPA03003354A (es) | Dispositivos medicos revestidos para el tratamiento de una enfermedad vascular. | |
NZ292854A (en) | Use of an photoactive compound to treat multiple sclerosis which is followed by light therapy | |
CY1105788T1 (el) | Χρηση του taci σαν παραγοντα καταπολεμησης ογκων | |
CY1108629T1 (el) | Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου | |
UY26456A1 (es) | Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen. | |
ES2062155T3 (es) | Composiciones para el tratamiento de neoplasia que contienen un agente antineoplasico y un agente protector reductor de efectos secundarios. | |
Montoro et al. | Infrared LED irradiation photobiomodulation of oxidative stress in human dental pulp cells | |
Floersheim et al. | Protection against ionising radiation and synergism with thiols by zinc aspartate | |
Adışen et al. | Ultraviolet A1 phototherapy in the treatment of early mycosis fungoides | |
BRPI0418157A (pt) | terapêutica de tumores alogênicos | |
UA86586C2 (ru) | Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом | |
ATE536178T1 (de) | Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis | |
BR0214196A (pt) | Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer | |
Grdina et al. | Relationships between cytoprotection and mutation prevention by WR-1065 | |
ATE442188T1 (de) | Bestrahlungseinrichtung | |
IL141160A0 (en) | A pharmaceutical composition containing a precursor of uric acid | |
DE60044092D1 (de) | Ungesättigte arylsulfone zum schutz von normalen zellen gegen die zytotoxische wirkung von chemotherapeutika | |
BR0312664A (pt) | Composição farmacêutica e uso da enzima urease para a fabricação de um medicamento para o tratamento de células cancerìgenas em um indivìduo | |
PE20011028A1 (es) | Combinacion oncolitica de acetildinalina y paclitaxel y/o carboplatino |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |